Universität zu Köln

Kobe, Carsten, Baues, Christian, Borchmann, Sven, Fuchs, Michael, Borchmann, Peter, Eich, Hans-Theodor and Dietlein, Markus (2022). FDG-positron emission tomography/computed tomography and new opportunities for risk stratification. Onkologie, 28 (10). S. 853 - 862. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234

Full text not available from this repository.

Abstract

Background To investigate the use of positron emission tomography/computed tomography with F-18-fluorodeoxyglucose (FDG-PET/CT) before, during, and after completion of chemotherapy, to optimize treatment intensity in Hodgkin lymphoma. Objectives FDG-PET/CT-adapted therapy concepts have been tested by the German Hodgkin Study Group (GHSG) in the multicenter studies HD15, HD16, HD17 and HD18. The HD15 trial investigated the omission of radiotherapy in FDG-PET/CT-negative residual tissue for advanced stages. The HD16 trial investigated a similar question for early stages, and the HD17 trial investigated intermediate stages. HD18 evaluated the possibility of reducing the number of chemotherapy cycles in PET-negative patients after 2 cycles of chemotherapy. Across stages, data from HD16, HD17, and HD18 were used to analyze the use of FDG-PET/CT in initial staging. Results Therapy stratification by FDG-PET/CT after completion of chemotherapy is safe in advanced stages of Hodgkin lymphoma as well as in intermediate stages. Also, FDG-PET/CT after 2 cycles of chemotherapy in advanced stages allows a reduction in the number of chemotherapy cycles. FDG-PET/CT is now the standard of care for staging prior to therapy initiation, not least because it allows bone marrow biopsy to be omitted. In contrast, omission of radiotherapy after less intensive chemotherapy in early stages of Hodgkin lymphoma has not become standard. Conclusion FDG-PET/CT is standard in staging before, during, and after chemotherapy of Hodgkin lymphoma.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Kobe, Carsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Baues, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, Sven UNSPECIFIED UNSPECIFIED UNSPECIFIED Fuchs, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Eich, Hans-Theodor UNSPECIFIED UNSPECIFIED UNSPECIFIED Dietlein, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-664362
DOI:	10.1007/s00761-022-01187-8
Journal or Publication Title:	Onkologie
Volume:	28
Number:	10
Page Range:	S. 853 - 862
Date:	2022
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	2731-7234
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language OPEN-LABEL; HODGKIN LYMPHOMA; RADIOTHERAPY; TRIAL Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66436